Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban and/or Colchicine for Outpatient COVID-19
NCT04516941Phase 3Terminated
- Sponsor
- Insel Gruppe
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of edoxaban, colchicine in coronavirus disease 2019 (COVID-19), sponsored by Insel Gruppe. Started Jan 2021; status: terminated.
02
Drugs
edoxabancolchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04516941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516941.